Intellipharmaceutics Notes Launch of 5mg Strength of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva

TORONTO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI ) (TSX: I ) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, based on information regarding recent generic introductions by Teva Pharmaceuticals ("Teva") on its website ( http://www.tevagenerics.com/products/new-teva-generics ) , it believes that Teva has launched a generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR ® , although the exact launch date by Teva is not known by the Company.

As previously announced, the Company had received a conditional approval from the U.S. Food and Drug Administration ("FDA") on November 18, 2013 to launch its own generic version of 5mg Focalin XR ® . It is understood by the Company that the conditional approval could be made final upon the expiry of six months from the date of marketplace launch in the United States by the company first to file for approval of the 5mg strength with the FDA. The Company believes that Teva is the company with that first-to-file exclusivity status.

If the Company receives a final approval to launch its generic version of the 5mg strength of Focalin XR ® six months after the date of launch of the 5mg strength by Teva, the Company believes that its manufacturing, marketing and distribution partner for Focalin XR ® generics in the United States, Par Pharmaceutical ("Par"), intends to launch this strength immediately upon the expiry of the exclusivity period, but there can be no assurance as to when or if any launch will occur.  

The Company is unable to predict or estimate, in respect of its generic of 5mg Focalin XR ® , a date of final FDA approval; an actual launch date, if any, by Par; the number of competitors then approved by the FDA to launch competing 5mg  generic products; any actual market penetration or market share; the market pricing or discounts which might then be in effect; or the amount and timing of revenues, if any, to which the Company may then be entitled under its distribution agreement with Par.

The CEO of Intellipharmaceutics, Dr. Isa Odidi, said, "We are very pleased, after waiting almost exactly one year since Teva received final approval, that Teva now appears to have launched its 5mg Focalin XR ® generic in the United States. Par now manufactures, markets and distributes the 15mg and 30mg strengths of generic Focalin XR ® , and we would be pleased to see the 5mg strength added to their portfolio."

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths) and product candidates in various stages of development, including Abbreviated New Drug Applications filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

Intellipharmaceutics also has New Drug Application 505(b)(2) product candidates in its development pipeline. These include Rexista™ oxycodone, an abuse-deterrent oxycodone, based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System and PODRAS™ Paradoxical Overdose Resistance Activating System, and Regabatin™ XR pregabalin extended-release capsules.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "intends," "could," or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities , our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies , products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies , products and product candidates, the scope of protection provided by intellectual property for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, the difficulty of predicting the impact of competitive products and pricing and the timing and success of product launches, the timing and amount of insurance reimbursement for our products, changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third party sourced products and materials, difficulties or delays in manufacturing, the manufacturing capacity of third-party manufacturers that we may use for our products , and the successful compliance with FDA and other governmental regulations applicable to the Company and its third party manufacturers' facilities, products and/or businesses . Additional risks and uncertainties relating to the Company and our business can be found in the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S ., which are available on www.sedar.com and www.sec.gov . The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document , and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: Intellipharmaceutics International Inc. Dr. Isa Odidi CEO and co-Chief Scientific Officer 416-798-3001 Investor Contact: ProActive Capital Kirin Smith 646-863-6519

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 0

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 126

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 95

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 288

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 94

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 153

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Exploring the Trading Landscape for Bitdeer Technologies

Updated Category News Views 99

Whales Are Bullish on Bitdeer Technologies Large investors, often referred to as whales, have shown a strong bullish sentiment towards Bitdeer Technologies. Recent observations from the options trading history reveal a total of eight significant trades in this period. Examining the nature of these trades indicates that approximately 62% were made with optimistic outlooks,...

Continue Reading
Successful Rafi's Amigos Golf Outing Raises Funds for JROTC

Updated Category News Views 188

Successful Fundraising at Rafi's Amigos Golf Outing On a recent day dedicated to supporting local youth, the Rafi's Amigos Golf Outing took place at Beavercreek Golf Club. Despite early rain, the weather brightened, allowing golfers and supporters to enjoy a seamless day on the course. With 116 participants, this year's event was recognized as a remarkable achievement,...

Continue Reading
Trinity Biotech Launches Innovative CGM Technology in India

Updated Category News Views 138

Trinity Biotech Prepares for CGM Launch in India Trinity Biotech plc (NASDAQ:TRIB), based in Dublin, is ready to make a notable stride in diabetes management with the launch of its advanced Continuous Glucose Monitoring (CGM) technology in India. The company has revealed plans for a crucial in-country study aimed at collecting feedback from diabetes patients and...

Continue Reading
Significant Market Growth for Fiberglass Fabrics Expected Soon

Updated Category News Views 259

Fiberglass Fabrics Market Growth Forecast A new market report reveals that the global fiberglass fabrics market is poised for substantial growth, projected to reach an increase of USD 2.83 billion between 2024 and 2028. This impressive expansion is expected to occur at a compound annual growth rate (CAGR) of 7.5% over the forecast period. The driving forces behind this...

Continue Reading
Earnings Insights for Hess Midstream: Key Metrics to Consider

Updated Category News Views 206

Anticipating Hess Midstream's Earnings Results Hess Midstream (NYSE:HESM) is gearing up to release its quarterly earnings report soon, poised to share vital insights that could impact investor sentiment. As the anticipation builds, understanding what to expect is crucial for current and prospective investors alike. Projected Earnings and Market Expectations Analysts are...

Continue Reading